AstraZeneca's Tagrisso just got the lung cancer nod it needs to hit $3B in sales

FDA
AZ's Tagrisso won the FDA's priority review tag in December. (FDA)

The future may still be uncertain for AstraZeneca’s Imfinzi in first-line lung cancer, but the company has picked up an approval in that setting for fellow portfolio med Tagrisso.

The FDA OK'd the product Thursday for patients with EGFR mutations, basing its decision on phase 3 data that rolled out in September at the European Society for Medical Oncology annual meeting. There, AZ showed Tagrisso could slash the risk of disease progression or death by 54% when facing off against standard-of-care tyrosine kinase inhibitors Tarceva from Roche and Iressa from AstraZeneca itself.

Tagrisso also staved off cancer progression for a median 18.9 months, compared with 10.2 months for the standard-of-care meds.

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

Those results in December helped the British drugmaker win the agency’s priority review tag, which sped up Tagrisso’s trip down the regulatory pathway.

RELATED: AstraZeneca's Tagrisso bests rivals at holding off EGFR lung cancer growth

Now, Tagrisso’s patient pool will widen well beyond its previous restrictions, which limited its use to patients with an abnormal T790M gene who had failed on other therapies. And with those boundaries out the window, AZ’s executives think they can hit a $3 billion sales target with the drug.

The company, which is working hard turn things around after a tough fall off the patent cliff, is hoping that’s the case—especially because it’s still unclear whether its immuno-oncology combo of Imfinzi and CTLA4 candidate tremelimumab will have a place in the first-line non-small cell lung cancer landscape. So far, the pairing's trial data has come up short, though AZ has encouraged investors to wait for overall survival results before drawing any conclusions.

RELATED: AstraZeneca's Mystic shortfall is an immuno-oncology shake-up for Bristol-Myers and a bolster for Merck and Roche

Even if the regimen does deliver data showing it can extend patients' lives, however, it’ll have to vie with Merck’s formidable Keytruda-chemo combo in the marketplace, and that cocktail has already shown it can improve survival significantly. Bristol-Myers Squibb, which recently touted positive early news for its own PD-1/PD-L1-CTLA4 duo, could give AstraZeneca a run for its money, too.

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.